Therefore, metastatic colon cancer cells harboring the combination of mutant KRAS along with MSI displayed a higher potential for forming TNTs, a highly relevant finding in light of recent evidence that MSI-high tumors are more strongly susceptible to immune checkpoint inhibitor therapy than microsatellite stable (MSS) tumors [47]. Here, KRAS is linked to malignant colon neoplasm.